Vetted Providers

Each provider in this directory is independently scored on a public six-dimension rubric: licensure, accreditation, transparency, product quality, pricing, and customer service. We verify state pharmacy licenses against state board registries, FDA enforcement actions against the FDA warning-letter database, and accreditations against the relevant public registry where one exists. Every score has a one-line rationale and (where possible) a source link on the provider profile. The full methodology is at /methodology/provider-vetting.

Some providers in this directory have an affiliate relationship with us. When a reader clicks through and books a consultation, we may earn a per-click or per-qualified-consult fee. Inclusion in the directory is independent of whether a provider pays us. The rubric and ranking are not affected by who pays. Affiliate relationships are disclosed on every listing card with a "We earn a fee" pill, and the methodology page lists every compensation type we accept (per-click and per-qualified-consult only — never per-prescription).

Yes, when prescribed by a licensed clinician and prepared by a state-licensed compounding pharmacy. Compounded versions are not FDA-approved (unlike brand-name Wegovy, Ozempic, Mounjaro, or Zepbound), but they are legally prepared at 503A pharmacies under individual prescriptions or at 503B FDA-registered outsourcing facilities. The legal landscape has evolved through 2025-2026; many telehealth providers offer both compounded and brand-name options. The FDA has not yet acted on most compounded telehealth platforms, but Eli Lilly and Novo Nordisk have filed lawsuits against several compounders over advertising claims.

We start with the highest-trafficked telehealth platforms in each category (compounded GLP-1, brand-name GLP-1, longevity clinics, peptide compounding) and work down. Reader suggestions are prioritized in the next review cycle — email us via /contact with a name and a link.

Because their weighted rubric score is higher. The score combines six dimensions with public weights: licensure (20%), accreditation (20%), transparency (20%), product quality (15%), pricing (15%), and customer service (10%). Each provider profile breaks down their score per dimension with a rationale, so you can see exactly which dimensions drove the ranking and disagree with specific scores if you want.

Public-record checks (state license, accreditation status, FDA warning letters) every quarter. The full Tier-3 questionnaire annually for active providers, and immediately whenever a major event happens (recall, regulatory action, ownership change, lawsuit). Each provider profile shows a "last verified" date so you can see how fresh the information is.

Email us at /contact with details. If it's a one-off we note it and watch for patterns. If it's representative of broader issues, the listing comes down or gets re-scored. We'd rather de-list a provider than defend one we shouldn't have listed.

It depends. Compounded GLP-1 medications aren't covered by insurance regardless of provider — the cash-pay model is the model. If you have insurance that covers brand-name Wegovy, Ozempic, or Zepbound, providers with insurance concierge support (like Ro) become much more attractive because your effective monthly cost can drop to $0–$25 with savings cards and prior authorization. We try to flag these tradeoffs in each provider's "Best for / Look elsewhere if" section.